Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 40

1.

Analysis of GDF15 and IGFBP7 in Hyperemesis Gravidarum Support Causality.

Fejzo MS, Fasching PA, Schneider MO, Schwitulla J, Beckmann MW, Schwenke E, MacGibbon KW, Mullin PM.

Geburtshilfe Frauenheilkd. 2019 Apr;79(4):382-388. doi: 10.1055/a-0830-1346. Epub 2019 Feb 26.

2.

Evidence GDF15 Plays a Role in Familial and Recurrent Hyperemesis Gravidarum.

Fejzo MS, Arzy D, Tian R, MacGibbon KW, Mullin PM.

Geburtshilfe Frauenheilkd. 2018 Sep;78(9):866-870. doi: 10.1055/a-0661-0287. Epub 2018 Sep 14.

3.

Placenta and appetite genes GDF15 and IGFBP7 are associated with hyperemesis gravidarum.

Fejzo MS, Sazonova OV, Sathirapongsasuti JF, Hallgrímsdóttir IB, Vacic V, MacGibbon KW, Schoenberg FP, Mancuso N, Slamon DJ, Mullin PM; 23andMe Research Team.

Nat Commun. 2018 Mar 21;9(1):1178. doi: 10.1038/s41467-018-03258-0.

4.

Critique of inaccurate reporting in Edlavitch article on "Publishing negative findings and the challenge of avoiding type II errors in studies of suspect teratogens: Example of a recent ondansetron publication".

Fejzo MS, MacGibbon KW, Mullin PM.

Reprod Toxicol. 2018 Jan;75:144-145. doi: 10.1016/j.reprotox.2017.11.007. Epub 2017 Nov 22. No abstract available.

PMID:
29174065
5.

Measures of depression and anxiety in women with hyperemesis gravidarum are flawed.

Fejzo MS.

Evid Based Nurs. 2017 Jul;20(3):78-79. doi: 10.1136/eb-2017-102686. Epub 2017 Jun 10. No abstract available.

PMID:
28601805
6.

Proteasome ubiquitin receptor PSMD4 is an amplification target in breast cancer and may predict sensitivity to PARPi.

Fejzo MS, Anderson L, Chen HW, Guandique E, Kalous O, Conklin D, Slamon DJ.

Genes Chromosomes Cancer. 2017 Aug;56(8):589-597. doi: 10.1002/gcc.22459. Epub 2017 May 4.

PMID:
28316110
7.

Genetic analysis of hyperemesis gravidarum reveals association with intracellular calcium release channel (RYR2).

Fejzo MS, Myhre R, Colodro-Conde L, MacGibbon KW, Sinsheimer JS, Reddy MVPL, Pajukanta P, Nyholt DR, Wright MJ, Martin NG, Engel SM, Medland SE, Magnus P, Mullin PM.

Mol Cell Endocrinol. 2017 Jan 5;439:308-316. doi: 10.1016/j.mce.2016.09.017. Epub 2016 Sep 20.

8.

Ondansetron in pregnancy and risk of adverse fetal outcomes in the United States.

Fejzo MS, MacGibbon KW, Mullin PM.

Reprod Toxicol. 2016 Jul;62:87-91. doi: 10.1016/j.reprotox.2016.04.027. Epub 2016 May 2.

PMID:
27151373
9.

Intestinal obstruction is a rare complication of ondansetron exposure in hyperemesis gravidarum.

Fejzo MS, MacGibbon K, Mullin P.

Reprod Toxicol. 2015 Nov;57:207. doi: 10.1016/j.reprotox.2015.07.071. Epub 2015 Jul 18. No abstract available.

PMID:
26196894
10.

ADRM1-amplified metastasis gene in gastric cancer.

Fejzo MS, Anderson L, Chen HW, Anghel A, Zhuo J, Anchoori R, Roden R, Slamon DJ.

Genes Chromosomes Cancer. 2015 Aug;54(8):506-515. doi: 10.1002/gcc.22262. Epub 2015 Jun 6.

PMID:
26052681
11.

Neurodevelopmental delay in children exposed in utero to hyperemesis gravidarum.

Fejzo MS, Magtira A, Schoenberg FP, Macgibbon K, Mullin PM.

Eur J Obstet Gynecol Reprod Biol. 2015 Jun;189:79-84. doi: 10.1016/j.ejogrb.2015.03.028. Epub 2015 Apr 2.

PMID:
25898368
12.

Psychiatric factors do not affect recurrence risk of hyperemesis gravidarum.

Magtira A, Schoenberg FP, MacGibbon K, Tabsh K, Fejzo MS.

J Obstet Gynaecol Res. 2015 Apr;41(4):512-6. doi: 10.1111/jog.12592. Epub 2014 Oct 27.

PMID:
25345812
13.

Antihistamines and other prognostic factors for adverse outcome in hyperemesis gravidarum.

Fejzo MS, Magtira A, Schoenberg FP, MacGibbon K, Mullin P, Romero R, Tabsh K.

Eur J Obstet Gynecol Reprod Biol. 2013 Sep;170(1):71-6. doi: 10.1016/j.ejogrb.2013.04.017. Epub 2013 Jun 7.

14.

Dacomitinib, an irreversible Pan-ErbB inhibitor significantly abrogates growth in head and neck cancer models that exhibit low response to cetuximab.

Ather F, Hamidi H, Fejzo MS, Letrent S, Finn RS, Kabbinavar F, Head C, Wong SG.

PLoS One. 2013;8(2):e56112. doi: 10.1371/journal.pone.0056112. Epub 2013 Feb 6.

15.

Amplification Target ADRM1: Role as an Oncogene and Therapeutic Target for Ovarian Cancer.

Fejzo MS, Anderson L, von Euw EM, Kalous O, Avliyakulov NK, Haykinson MJ, Konecny GE, Finn RS, Slamon DJ.

Int J Mol Sci. 2013 Feb 1;14(2):3094-109. doi: 10.3390/ijms14023094.

16.

No increased risk of psychological/behavioral disorders in siblings of women with hyperemesis gravidarum (HG) unless their mother had HG.

Mullin PM, Bray A, Vu V, Schoenberg-Paik F, MacGibbon K, Romero R, Goodwin TM, Fejzo MS.

J Dev Orig Health Dis. 2012 Oct;3(5):375-9. doi: 10.1017/S2040174412000220.

PMID:
25102267
17.

Hyperemesis gravidarum: it is time to put an end to the misguided theory of a psychiatric etiology.

Fejzo MS, Macgibbon K.

Gen Hosp Psychiatry. 2012 Nov-Dec;34(6):699-700; author reply 700-1. doi: 10.1016/j.genhosppsych.2012.06.019. Epub 2012 Aug 13. No abstract available.

PMID:
22898444
18.

Change in paternity and recurrence of hyperemesis gravidarum.

Fejzo MS, Ching C, Schoenberg FP, Macgibbon K, Romero R, Goodwin TM, Mullin PM.

J Matern Fetal Neonatal Med. 2012 Aug;25(8):1241-5. doi: 10.3109/14767058.2011.632039. Epub 2011 Nov 24.

19.

Risk factors, treatments, and outcomes associated with prolonged hyperemesis gravidarum.

Mullin PM, Ching C, Schoenberg F, MacGibbon K, Romero R, Goodwin TM, Fejzo MS.

J Matern Fetal Neonatal Med. 2012 Jun;25(6):632-6. doi: 10.3109/14767058.2011.598588. Epub 2011 Sep 15.

20.

Prenatal exposure to hyperemesis gravidarum linked to increased risk of psychological and behavioral disorders in adulthood.

Mullin PM, Bray A, Schoenberg F, MacGibbon KW, Romero R, Goodwin TM, Fejzo MS.

J Dev Orig Health Dis. 2011 Aug;2(4):200-4. doi: 10.1017/S2040174411000249.

PMID:
25141163
21.

Posttraumatic stress symptoms following pregnancy complicated by hyperemesis gravidarum.

Christodoulou-Smith J, Gold JI, Romero R, Goodwin TM, Macgibbon KW, Mullin PM, Fejzo MS.

J Matern Fetal Neonatal Med. 2011 Nov;24(11):1307-11. doi: 10.3109/14767058.2011.582904. Epub 2011 Jun 3.

22.

Knockdown of ovarian cancer amplification target ADRM1 leads to downregulation of GIPC1 and upregulation of RECK.

Fejzo MS, Ginther C, Dering J, Anderson L, Venkatesan N, Konecny G, Karlan B, Slamon DJ.

Genes Chromosomes Cancer. 2011 Jun;50(6):434-41. doi: 10.1002/gcc.20868. Epub 2011 Mar 22.

PMID:
21432940
23.

Recurrence risk of hyperemesis gravidarum.

Fejzo MS, Macgibbon KW, Romero R, Goodwin TM, Mullin PM.

J Midwifery Womens Health. 2011 Mar-Apr;56(2):132-6. doi: 10.1111/j.1542-2011.2010.00019.x. Epub 2011 Mar 1.

24.

Familial aggregation of hyperemesis gravidarum.

Zhang Y, Cantor RM, MacGibbon K, Romero R, Goodwin TM, Mullin PM, Fejzo MS.

Am J Obstet Gynecol. 2011 Mar;204(3):230.e1-7. doi: 10.1016/j.ajog.2010.09.018. Epub 2010 Oct 25.

25.

Tissue microarrays from frozen tissues-OCT technique.

Fejzo MS, Slamon DJ.

Methods Mol Biol. 2010;664:73-80. doi: 10.1007/978-1-60761-806-5_8.

PMID:
20690054
26.

Periostin promotes ovarian cancer angiogenesis and metastasis.

Zhu M, Fejzo MS, Anderson L, Dering J, Ginther C, Ramos L, Gasson JC, Karlan BY, Slamon DJ.

Gynecol Oncol. 2010 Nov;119(2):337-44. doi: 10.1016/j.ygyno.2010.07.008. Epub 2010 Aug 4.

PMID:
20688362
27.

Lapatinib, a dual EGFR and HER2 kinase inhibitor, selectively inhibits HER2-amplified human gastric cancer cells and is synergistic with trastuzumab in vitro and in vivo.

Wainberg ZA, Anghel A, Desai AJ, Ayala R, Luo T, Safran B, Fejzo MS, Hecht JR, Slamon DJ, Finn RS.

Clin Cancer Res. 2010 Mar 1;16(5):1509-19. doi: 10.1158/1078-0432.CCR-09-1112. Epub 2010 Feb 23.

28.

Symptoms and pregnancy outcomes associated with extreme weight loss among women with hyperemesis gravidarum.

Fejzo MS, Poursharif B, Korst LM, Munch S, MacGibbon KW, Romero R, Goodwin TM.

J Womens Health (Larchmt). 2009 Dec;18(12):1981-7. doi: 10.1089/jwh.2009.1431.

29.

Patients with a history of hyperemesis gravidarum have similar symptoms during egg stimulation and develop ovarian hyperstimulation syndrome: case series.

Fejzo MS, Romero R, Goodwin TM.

Fertil Steril. 2010 Jan;93(1):267.e9-11. doi: 10.1016/j.fertnstert.2009.09.022. Epub 2009 Oct 29.

30.

High prevalence of severe nausea and vomiting of pregnancy and hyperemesis gravidarum among relatives of affected individuals.

Fejzo MS, Ingles SA, Wilson M, Wang W, MacGibbon K, Romero R, Goodwin TM.

Eur J Obstet Gynecol Reprod Biol. 2008 Nov;141(1):13-7. doi: 10.1016/j.ejogrb.2008.07.003. Epub 2008 Aug 26.

31.

Comprehensive analysis of 20q13 genes in ovarian cancer identifies ADRM1 as amplification target.

Fejzo MS, Dering J, Ginther C, Anderson L, Ramos L, Walsh C, Karlan B, Slamon DJ.

Genes Chromosomes Cancer. 2008 Oct;47(10):873-83. doi: 10.1002/gcc.20592.

PMID:
18615678
32.

Activity of lapatinib a novel HER2 and EGFR dual kinase inhibitor in human endometrial cancer cells.

Konecny GE, Venkatesan N, Yang G, Dering J, Ginther C, Finn R, Rahmeh M, Fejzo MS, Toft D, Jiang SW, Slamon DJ, Podratz KC.

Br J Cancer. 2008 Mar 25;98(6):1076-84. doi: 10.1038/sj.bjc.6604278. Epub 2008 Mar 11.

33.

Secular trends in the treatment of hyperemesis gravidarum.

Goodwin TM, Poursharif B, Korst LM, MacGibbon KW, Romero R, Fejzo MS.

Am J Perinatol. 2008 Mar;25(3):141-7. doi: 10.1055/s-2008-1040344. Epub 2008 Feb 7.

PMID:
18260047
34.

Elective pregnancy termination in a large cohort of women with hyperemesis gravidarum.

Poursharif B, Korst LM, Macgibbon KW, Fejzo MS, Romero R, Goodwin TM.

Contraception. 2007 Dec;76(6):451-5. Epub 2007 Nov 9.

PMID:
18061703
35.

The psychosocial burden of hyperemesis gravidarum.

Poursharif B, Korst LM, Fejzo MS, MacGibbon KW, Romero R, Goodwin TM.

J Perinatol. 2008 Mar;28(3):176-81. Epub 2007 Dec 6.

PMID:
18059463
36.

The hD52 (TPD52) gene is a candidate target gene for events resulting in increased 8q21 copy number in human breast carcinoma.

Balleine RL, Fejzo MS, Sathasivam P, Basset P, Clarke CL, Byrne JA.

Genes Chromosomes Cancer. 2000 Sep;29(1):48-57.

PMID:
10918393
37.

Characterization of genes encoding known and novel human mast cell tryptases on chromosome 16p13.3.

Pallaoro M, Fejzo MS, Shayesteh L, Blount JL, Caughey GH.

J Biol Chem. 1999 Feb 5;274(6):3355-62.

38.

Molecular cytogenetic analysis of consistent abnormalities at 8q12-q22 in breast cancer.

Fejzo MS, Godfrey T, Chen C, Waldman F, Gray JW.

Genes Chromosomes Cancer. 1998 Jun;22(2):105-13.

PMID:
9598797
39.

Disruption of the architectural factor HMGI-C: DNA-binding AT hook motifs fused in lipomas to distinct transcriptional regulatory domains.

Ashar HR, Fejzo MS, Tkachenko A, Zhou X, Fletcher JA, Weremowicz S, Morton CC, Chada K.

Cell. 1995 Jul 14;82(1):57-65.

40.

Identification of a YAC spanning the translocation breakpoints in uterine leiomyomata, pulmonary chondroid hamartoma, and lipoma: physical mapping of the 12q14-q15 breakpoint region in uterine leiomyomata.

Fejzo MS, Yoon SJ, Montgomery KT, Rein MS, Weremowicz S, Krauter KS, Dorman TE, Fletcher JA, Mao JI, Moir DT, et al.

Genomics. 1995 Mar 20;26(2):265-71.

PMID:
7601452

Supplemental Content

Loading ...
Support Center